Eiken Chemical Co., Ltd. · TSE:4549
Eiken Chemical — FY2011 Earnings Presentation
32 slides from Eiken Chemical's earnings presentation, Apr 27, 2012
Slide 1: The business performance briefing for the term ended Mar. 2012
The business performance briefing for the term ended Mar. 2012 (the 74th term) EIKEN CHEMICAL CO., LTD. EIKEN CHEMICAL CO., LTD Apr. 27, 2012
Slide 2: Operating Results for the term ended Mar. 2012
２ Operating Results for the term ended Mar. 2012 (the 74th term)
Slide 3: Consolidated performance for the term ended Mar. 2012
Consolidated performance for the term ended Mar. 2012 (the 74th term)３ (Millions of yen) Term ended Mar. 2012 Difference from target YoY change Target value Actual results Ratio value Net sales 27,610 27,702 100.0% 92 140 Operating 2,210 2,363 8.5% 153 (346) income Ordinary income 2,280 2,543 9.2% 2
Slide 4: Consolidated sales for product category: Fecal occult blood diagnostic reagents
Consolidated sales for product category 4 (Millions of yen) Fecal occult blood Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 diagnostic reagents (OC) First half Full year First half Full year First half Full year 3,293 5,826 3,332 5,994 3,406 6,038 ●0.7% increase from the 5,994 6,03
Slide 5: Consolidated sales for product category: Immunological and serological reagents
Consolidated sales for product category 5 (Millions of yen) Immunological and Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 serological reagents First half Full year First half Full year First half Full year 4,419 8,626 4,532 8,909 4,588 9,076 8,909 9,076 8,626 Full year ● 1.9% incr
Slide 6: Consolidated sales for product category: Microbiological reagents
Consolidated sales for product category 6 (Millions of yen) Microbiological reagents Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 First half Full year First half Full year First half Full year 2,271 4,449 2,298 4,651 2,315 4,544 4,651 4,449 4,544 ● 2.3% decrease from the Full year
Slide 7: Consolidated sales for product category: Dry chemistry reagents
Consolidated sales for product category 7 (Millions of yen) Dry chemistry reagents Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 First half Full year First half Full year First half Full year 981 1,873 1,001 1,948 1,001 1,972 1,948 1,972 ● 1.2% increase from the 1,873 Full year corr
Slide 8: Consolidated sales for product category: Clinical chemistry reagents
Consolidated sales for product category 8 (Millions of yen) Clinical chemistry reagents Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 First half Full year First half Full year First half Full year 455 864 418 808 382 739 ● 8.5% decrease from the 864 Full year 808 corresponding term
Slide 9: Consolidated sales for product category: Culture media
Consolidated sales for product category 9 (Millions of yen) Culture media for Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 equipment, food and First half Full year First half Full year First half Full year environment category 1,321 2,552 1,236 2,441 1,195 2,360 2,552 2,441 Full ye
Slide 10: Consolidated sales for product category: Medical devices
Consolidated sales for product category １0 (Millions of yen) Medical devices Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 First half Full year First half Full year First half Full year 984 2,316 1,033 2,387 998 2,326 2,387 2,316 2,326 Full year ● 2.6% decrease from the correspondin
Slide 11: Consolidated sales for product category: Molecular genetics
Consolidated sales for product category 11 (Millions of yen) Molecular genetics Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 （include devices） First half Full year First half Full year First half Full year 182 412 185 508 266 769 769 ● 51.4% increase from the corresponding term in
Slide 12: Consolidated overseas sales
Consolidated overseas sales １2 (Millions of yen) Overseas sales Term ended Mar. 2010 Term ended Mar. 2011 Term ended Mar. 2012 First half Full year First half Full year First half Full year 709 1,632 686 1,689 786 1,693 Sales Sales for product category ● 0.2% increase from the corresponding ● Increa
Slide 13: Consolidated overseas sales by region
Consolidated overseas sales １3 Europe North America 665 651 649 583 561 559 Full year Full year 281 275 279 287 275 First half 201 First half Term ended Mar. Term ended Mar. Term ended Mar. Term ended Mar. Term ended Mar. Term ended Mar. 2010 2011 2012 2010 2011 2012 Asia etc. 482 455 407 Full year
Slide 14: Consolidated balance sheets
Consolidated balance sheets １4 Term ended Mar. 2012 Main reasons of increase/decrease Term ended Mar. 2011 Current liabilities Current asetts 9,498 Cash and deposits (750) （+93） Notes and account receivable 532 Current liabilities 9,405 Inventories 144 Current assets Noncurrent Other-CA (306) 19,856
Slide 15: Consolidated cash flows
Consolidated cash flows １5 (Millions of yen) Term ended Mar. 2011 Term ended Mar. 2012 Cash and cash equivalents at beginning of the period 7,037 6,045 Net cash provided by (used in) operating activities 2,212 1,713 Net cash provided by (used in) investing activities (4,127) (1,634) Net cash provide
Slide 16: R&D cost and investment in equipment (consolidated)
R&D cost and investment in equipment (consolidated) １6 First half Full year R&D cost Investment in equipment Depreciation and amortization (Millions of yen) (Millions of yen) (Millions of yen) 4,243 2,220 1,016 1,924 1,884 922 923 2,122 927 915 479 886 1,421 444 422 690 532 295 Term ended Term ended
Slide 17: Primary strategies for the term ended Mar. 2012
１7 Primary strategies for the term ended Mar. 2012 (the 74th term)
Slide 18: Primary strategies: sales promotion in Japan
Primary strategies for the term ended Mar. 2012 (the 74th term) １8 Promotion of the sale measure Japan ・ Strengthening of sales promotion system for our major products （OC, LZ, LAMP, AIA etc.） ∇Promotion of ABC Examination mainly at checkup centers and facilities. ∇Launch and sales promotion of LAMP
Slide 19: Primary strategies: sales promotion in U.S. and Europe
Primary strategies for the term ended Mar. 2012 (the 74th term) 19 Promotion of the sale measure U. S. ・ Expand OC reagents and medical devices ・ LAMP: Entry to the food product inspection field ∇ AOAC certificate （during a reexamination and evaluation） Europe ・ Expand OC reagents and medical device
Slide 20: Primary strategies: Asia and China
Primary strategies for the term ended Mar. 2012 (the 74th term) 20 Promotion of the sale measure Asia, etc ・ Expand OC reagents and medical devices ∇Adoption decision of the OC prescreening in New Zealand ∇ Research activity of the OC Screening bid in Australia China ・Full scale operation of the pro
Slide 21: Primary strategies: R&D and new products
Primary strategies for the term ended Mar. 2012 (the 74th term) 21 R&D and new products （１）Improvement of products by existing technologies （２）Enrich the lineup of LAMP products 【Clinical diagnostics】 ・Launch of “Loopamp® MTBC Detection Kit”: June 2011 Insurance application : Oct. 1, 2011 ・Mycoplasm
Slide 22: Primary strategies: FIND business
Primary strategies for the term ended Mar. 2012 (the 74th term) 22 FIND business （１） Tuberculosis test 【In Japan】June 1, 2011 Launch of “Loopamp® MTBC Detection Kit” 【Outside Japan】 Demonstration Study started in Peru, Uganda and India （２）Malaria ・Evaluation Study started （３）HAT (Human African Typan
Slide 23: Primary strategies: productivity and human resources
Primary strategies for the term ended Mar. 2012 (the 74th term) 23 Improvements in productivity and development of human resources （1）Reorganization of the production base ∇Closure of Togane plant and sellout of Oji office ∇Gradual concentration at the Nogi Plant ∇Establishment of the operation mana
Slide 24: Return to shareholders (dividend)
Return to shareholders (dividend) 24 Term-end dividend: 18 yen per share ( Dividend increase +5yen） Consolidated total dividends (annual) : 544 Millions of yen Consolidated payout ratio: 37.3% Interim dividend Term-end dividend (yen) Commemorative Special dividend dividend 5 yen 5 yen (term-end) (in
Slide 25: Primary strategies and earnings forecast for the term ending Mar. 2013
25 Primary strategies and earnings forecast for the term ending Mar. 2013 (the 75th term)
Slide 26: Sales promotion
Primary strategies and earnings forecast for the term ending 26 Mar. 2013 (the 75th term) Sales promotion （1）Domestic market ・ Strengthening of sales promotion system for our major products ∇OC Products ∇LZ reagents for ABC examination, MMP-3 ∇LAMP reagents reagent for respiratory infectious disease
Slide 27: China and FIND plans
Primary strategies and earnings forecast for the term ending 27 Mar. 2013 (the 75th term) China （１）EIKEN CHINA CO., LTD. start of production of LAMP reagents. FIND （1）Tuberculosis test 2012 First half Strategic And Technical Advisory Group For Tuberculosis Meeting * Application procedures to obtain
Slide 28: R&D strengthening and productivity improvement
Primary strategies and earnings forecast for the term ending 28 Mar. 2013 (the 75th term) Strengthening of research and development （1）Promotion of development of LAMP products, BLEIA products, POCT products （2）Improvement of the products by brushing up the existing technology Improvement in product
Slide 29: R&D cost and investment in equipment (consolidated)
R&D cost and investment in equipment (consolidated) 29 R&D cost Investment in equipment Depreciation and amortization (Millions of yen) (Millions of yen) (Millions of yen) 4,243 2,220 1,126 2,087 1,016 1,884 923 2,122 709 Term ended Term ended Term ended Term ended Term ended Term ended Term ended T
Slide 30: Consolidated earnings forecast for the term ending Mar. 2013
Consolidated earnings forecast for the term ending 30 Mar. 2013 (the 75th term) Target value (Millions of yen) Consolidated Non-consolidated Amount Ratio [%] YoY change [%] Amount Ratio [%] YoY change [%] Net sales 28,000 101.1% 27,970 101.0% Operating income 2,460 8.8% 104.1% 2,440 8.7% 103.5% Ordi
Slide 31: EIKEN CHEMICAL CO., LTD.
31 EIKEN CHEMICAL CO., LTD. We protect the health of the public through health care services http://www.eiken.co.jp
Slide 32: Notes
32 Notes This document is not the disclosed reference for financial instruments and exchange. Its accuracy and integrity are not guaranteed. The estimates, etc. written in this document are based on currently available information, and so actual values may be different due to various factors. This d